Cogent Biosciences (COGT) Change in Cash (2017 - 2026)

Cogent Biosciences (COGT) has reported Change in Cash for 10 consecutive years, with -$70.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash fell 354.34% year-over-year to -$70.8 million; the TTM figure through Mar 2026 stood at $115.6 million (up 228.76% YoY), while the FY2025 annual figure was $214.3 million, up 376.82% from the prior year.
• Change in Cash retreated to -$70.8 million in Q1 2026 per COGT's latest filing, from $186.8 million in the prior quarter.
• Across five years, Change in Cash topped out at $186.8 million in Q4 2025 and bottomed at -$185.0 million in Q3 2022.
• Historically, Change in Cash has averaged $1.2 million across 5 years, with a median of $1.1 million in 2024.
• Annual changes were most pronounced in 2023 — Change in Cash slumped 4823.9% — and 2025, when it jumped 16578.12%.
• Cogent Biosciences' Change in Cash stood at -$682000.0 in 2022, then plunged by 4823.9% to -$33.6 million in 2023, then soared by 103.34% to $1.1 million in 2024, then surged by 16578.12% to $186.8 million in 2025, then plunged by 137.9% to -$70.8 million in 2026.
• Business Quant data shows COGT's Change in Cash at -$70.8 million in Q1 2026, $186.8 million in Q4 2025, and -$2.0 million in Q3 2025.